Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Sus scrofa | Pepsin A | Starlite/ChEMBL | References |
Rhizopus microsporus var. chinensis | Rhizopuspepsin | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Dictyostelium discoideum | hypothetical protein | Rhizopuspepsin | 393 aa | 337 aa | 24.3 % |
Cryptosporidium hominis | aspartyl protease precursor | Pepsin A | 385 aa | 345 aa | 31.9 % |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | Pepsin A | 385 aa | 332 aa | 42.5 % |
Plasmodium berghei | plasmepsin IV | Pepsin A | 385 aa | 369 aa | 31.7 % |
Plasmodium falciparum | plasmepsin VII | Pepsin A | 385 aa | 423 aa | 27.7 % |
Schistosoma mansoni | memapsin-2 (A01 family) | Pepsin A | 385 aa | 434 aa | 21.4 % |
Babesia bovis | aspartyl protease, putative | Pepsin A | 385 aa | 327 aa | 28.7 % |
Theileria parva | cathepsin E, putative | Pepsin A | 385 aa | 390 aa | 33.3 % |
Plasmodium vivax | plasmepsin V, putative | Pepsin A | 385 aa | 410 aa | 22.9 % |
Plasmodium knowlesi | aspartyl protease, putative | Pepsin A | 385 aa | 366 aa | 27.9 % |
Candida albicans | secretory aspartyl proteinase SAP2p | Pepsin A | 385 aa | 346 aa | 30.9 % |
Cryptosporidium parvum | secreted pepsinogen like aspartyl protease having a signal peptide | Rhizopuspepsin | 393 aa | 412 aa | 20.9 % |
Plasmodium falciparum | plasmepsin II | Pepsin A | 385 aa | 323 aa | 31.6 % |
Candida albicans | secretory aspartyl proteinase SAP1p | Pepsin A | 385 aa | 331 aa | 31.1 % |
Echinococcus multilocularis | cathepsin d (lysosomal aspartyl protease) | Pepsin A | 385 aa | 330 aa | 43.9 % |
Onchocerca volvulus | Pepsin A | 385 aa | 382 aa | 33.0 % | |
Candida albicans | secretory aspartyl proteinase SAP5p | Pepsin A | 385 aa | 332 aa | 28.9 % |
Cryptosporidium parvum | membrane bound aspartyl proteinase with a signal peptide plus transmembrane domain | Pepsin A | 385 aa | 346 aa | 31.8 % |
Plasmodium yoelii | plasmepsin | Pepsin A | 385 aa | 326 aa | 32.8 % |
Babesia bovis | eukaryotic aspartyl protease family protein | Pepsin A | 385 aa | 365 aa | 32.3 % |
Candida albicans | vacuolar aspartic proteinase precursor similar to S. cerevisiae PEP4 (YPL154C) | Pepsin A | 385 aa | 325 aa | 42.8 % |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | Pepsin A | 385 aa | 382 aa | 33.5 % |
Candida albicans | secretory aspartyl proteinase SAP5p | Pepsin A | 385 aa | 332 aa | 28.9 % |
Plasmodium knowlesi | plasmepsin V, putative | Pepsin A | 385 aa | 418 aa | 21.5 % |
Candida albicans | secretory aspartyl proteinase SAP10p, related to SAP9p | Pepsin A | 385 aa | 378 aa | 27.2 % |
Schistosoma mansoni | cathepsin D (A01 family) | Pepsin A | 385 aa | 373 aa | 43.7 % |
Onchocerca volvulus | Sphingomyelin phosphodiesterase 1 homolog | Pepsin A | 385 aa | 386 aa | 42.0 % |
Candida albicans | secretory aspartyl proteinase SAP1p | Pepsin A | 385 aa | 331 aa | 31.1 % |
Candida albicans | vacuolar aspartic proteinase precursor similar to S. cerevisiae PEP4 (YPL154C) | Pepsin A | 385 aa | 325 aa | 42.8 % |
Onchocerca volvulus | Pepsin A | 385 aa | 370 aa | 21.4 % | |
Toxoplasma gondii | eukaryotic aspartyl protease superfamily protein | Pepsin A | 385 aa | 363 aa | 25.3 % |
Plasmodium falciparum | plasmepsin IV | Pepsin A | 385 aa | 323 aa | 32.2 % |
Brugia malayi | aspartic protease BmAsp-1, identical | Pepsin A | 385 aa | 385 aa | 33.0 % |
Schistosoma mansoni | cathepsin D (A01 family) | Pepsin A | 385 aa | 375 aa | 43.7 % |
Neospora caninum | Cathepsin D enzyme (EC 3.4.23.5), related | Pepsin A | 385 aa | 353 aa | 28.3 % |
Babesia bovis | aspartyl protease, putative | Rhizopuspepsin | 393 aa | 321 aa | 21.2 % |
Candida albicans | secretory aspartyl proteinase SAP4p | Pepsin A | 385 aa | 341 aa | 27.9 % |
Plasmodium falciparum | plasmepsin I | Pepsin A | 385 aa | 366 aa | 30.3 % |
Candida albicans | secretory aspartyl proteinase SAP10p, related to SAP9p | Pepsin A | 385 aa | 378 aa | 27.2 % |
Schistosoma japonicum | ko:K01379 cathepsin D [EC3.4.23.5], putative | Pepsin A | 385 aa | 376 aa | 43.1 % |
Candida albicans | secretory aspartyl proteinase SAP8p | Pepsin A | 385 aa | 358 aa | 30.7 % |
Plasmodium knowlesi | plasmepsin IV, putative | Pepsin A | 385 aa | 323 aa | 31.0 % |
Plasmodium yoelii | aspartyl protease-like | Pepsin A | 385 aa | 419 aa | 21.0 % |
Candida albicans | secretory aspartyl proteinase SAP3p | Pepsin A | 385 aa | 368 aa | 27.4 % |
Plasmodium berghei | plasmepsin V, putative | Pepsin A | 385 aa | 412 aa | 22.1 % |
Plasmodium berghei | plasmepsin VII | Pepsin A | 385 aa | 410 aa | 28.5 % |
Toxoplasma gondii | aspartyl protease ASP1 | Pepsin A | 385 aa | 410 aa | 29.5 % |
Neospora caninum | Renin, related | Pepsin A | 385 aa | 355 aa | 29.3 % |
Candida albicans | secretory aspartyl proteinase SAP6p | Pepsin A | 385 aa | 342 aa | 27.5 % |
Drosophila melanogaster | CG31926 gene product from transcript CG31926-RB | Pepsin A | 385 aa | 332 aa | 40.4 % |
Onchocerca volvulus | Putative 6-pyruvoyl tetrahydrobiopterin synthase | Pepsin A | 385 aa | 386 aa | 31.9 % |
Neospora caninum | Pepsinogen A1, related | Pepsin A | 385 aa | 380 aa | 33.9 % |
Candida albicans | potential aspartic protease, weakly similar to C terminus of S. cerevisiae YPS1 (YLR120C), GPI-anchored protease | Pepsin A | 385 aa | 336 aa | 22.6 % |
Schistosoma japonicum | Lysosomal aspartic protease precursor, putative | Pepsin A | 385 aa | 324 aa | 31.2 % |
Candida albicans | secretory aspartyl proteinase SAP7p | Pepsin A | 385 aa | 361 aa | 26.9 % |
Toxoplasma gondii | aspartyl protease | Pepsin A | 385 aa | 409 aa | 31.5 % |
Candida albicans | secretory aspartyl proteinase SAP3p | Pepsin A | 385 aa | 368 aa | 27.4 % |
Plasmodium knowlesi | eukaryotic aspartyl protease, putative | Rhizopuspepsin | 393 aa | 340 aa | 23.8 % |
Candida albicans | secretory aspartyl proteinase SAP6p | Pepsin A | 385 aa | 342 aa | 27.5 % |
Dictyostelium discoideum | hypothetical protein | Pepsin A | 385 aa | 377 aa | 29.2 % |
Schistosoma japonicum | Cathepsin D precursor, putative | Pepsin A | 385 aa | 328 aa | 37.8 % |
Echinococcus granulosus | cathepsin d lysosomal aspartyl protease | Pepsin A | 385 aa | 330 aa | 44.5 % |
Plasmodium falciparum | plasmepsin VI | Pepsin A | 385 aa | 397 aa | 31.5 % |
Plasmodium knowlesi | aspartyl protease, putative | Pepsin A | 385 aa | 391 aa | 31.5 % |
Candida albicans | potential aspartic protease, weakly similar to C terminus of S. cerevisiae YPS1 (YLR120C), GPI-anchored protease | Pepsin A | 385 aa | 336 aa | 22.6 % |
Plasmodium falciparum | plasmepsin III | Pepsin A | 385 aa | 363 aa | 26.2 % |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | Pepsin A | 385 aa | 377 aa | 30.0 % |
Neospora caninum | hypothetical protein | Rhizopuspepsin | 393 aa | 327 aa | 23.9 % |
Candida albicans | secretory aspartyl proteinase SAP2p | Pepsin A | 385 aa | 346 aa | 30.9 % |
Loa Loa (eye worm) | aspartic protease BmAsp-1 | Pepsin A | 385 aa | 406 aa | 29.3 % |
Loa Loa (eye worm) | aspartic protease BmAsp-2 | Pepsin A | 385 aa | 385 aa | 44.2 % |
Plasmodium vivax | plasmepsin IV, putative | Pepsin A | 385 aa | 323 aa | 30.0 % |
Candida albicans | secretory aspartyl proteinase SAP4p | Pepsin A | 385 aa | 341 aa | 27.9 % |
Plasmodium vivax | aspartyl proteinase, putative | Pepsin A | 385 aa | 380 aa | 32.1 % |
Candida albicans | secretory aspartyl proteinase SAP8p | Pepsin A | 385 aa | 358 aa | 30.7 % |
Plasmodium berghei | plasmepsin VI | Pepsin A | 385 aa | 351 aa | 31.9 % |
Plasmodium vivax | aspartyl protease, putative | Pepsin A | 385 aa | 365 aa | 27.7 % |
Candida albicans | secretory aspartyl proteinase SAP7p | Pepsin A | 385 aa | 361 aa | 26.9 % |
Drosophila melanogaster | CG6508 gene product from transcript CG6508-RA | Pepsin A | 385 aa | 379 aa | 41.4 % |
Toxoplasma gondii | aspartyl protease ASP3 | Rhizopuspepsin | 393 aa | 336 aa | 24.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | aspartyl protease, putative | 0.0133 | 0.2691 | 1 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0217 | 1 | 1 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0102 | 0 | 0.5 |
Schistosoma mansoni | methionine-tRNA synthetase | 0.0143 | 0.3501 | 0.3501 |
Loa Loa (eye worm) | hypothetical protein | 0.0143 | 0.3501 | 1 |
Loa Loa (eye worm) | glycyl-tRNA synthetase | 0.0111 | 0.0729 | 0.2083 |
Entamoeba histolytica | methionyl-tRNA synthetase, putative | 0.0143 | 0.3501 | 0.5 |
Schistosoma mansoni | glycyl-tRNA synthetase | 0.0111 | 0.0729 | 0.0729 |
Plasmodium falciparum | plasmepsin IX | 0.0133 | 0.2691 | 1 |
Plasmodium vivax | aspartyl protease, putative | 0.0133 | 0.2691 | 1 |
Plasmodium falciparum | plasmepsin X | 0.0133 | 0.2691 | 1 |
Toxoplasma gondii | aspartyl protease ASP3 | 0.0133 | 0.2691 | 1 |
Loa Loa (eye worm) | multisynthetase complex auxiliary component p43 | 0.012 | 0.1524 | 0.4354 |
Echinococcus multilocularis | methionyl tRNA synthetase, cytoplasmic | 0.0143 | 0.3501 | 1 |
Loa Loa (eye worm) | bifunctional aminoacyl-tRNA synthetase | 0.0111 | 0.0729 | 0.2083 |
Echinococcus granulosus | glycyl tRNA synthetase | 0.0111 | 0.0729 | 0.2083 |
Chlamydia trachomatis | methionine--tRNA ligase | 0.0143 | 0.3501 | 0.5 |
Treponema pallidum | methionyl-tRNA synthetase | 0.0143 | 0.3501 | 0.5 |
Brugia malayi | methionyl-tRNA synthetase | 0.0143 | 0.3501 | 1 |
Echinococcus granulosus | methionyl tRNA synthetase cytoplasmic | 0.0143 | 0.3501 | 1 |
Echinococcus multilocularis | glycyl tRNA synthetase | 0.0111 | 0.0729 | 0.2083 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.2 uM | Inhibitory concentration against porcine pepsin | ChEMBL. | 11806706 |
IC50 (binding) | = 0.2 uM | Inhibitory concentration against porcine pepsin | ChEMBL. | 11806706 |
IC50 (functional) | = 2 uM | Inhibitory concentration against R. chinensis pepsin | ChEMBL. | 11806706 |
IC50 (functional) | = 2 uM | Inhibitory concentration against R. chinensis pepsin | ChEMBL. | 11806706 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.